Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
Original title: “7 companies hiring in New York now”
Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
Original title: “Incyte cuts early-stage cancer drug to focus on next-gen programs”
Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”
Original title: “Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court”
The FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outline ambitious plans in second quarter presentations; Sarepta taps Michael Severino as its new CEO; and Amgen launches its official defense of Tavneos.
Original title: “Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more”
With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
Original title: “Biotechs bring big launches and pharma rivalries into Q2 earnings period”
Drug discovery teams have more data than ever, but turning that data into actionable insight remains a major challenge. In this candid conversation, Patsnap’s Ben Coverdale is joined by Mark Davies, Head of Product for Life Sciences, and James Longden, Senior Director, Life Sciences at Evolvus to explore how AI-powered intelligence is reshaping candidate optimization across antibodies, ADCs, and peptides.
Original title: “Webinar: Building the Intelligence Engine for Drug Discovery R&D Teams”
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.
Original title: “GSK prepares for patent cliff with $2.5B cost-cutting plan”
Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
Original title: “Oak Hill takes SPAC track to Nasdaq with Roche asset in tow”
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
Original title: “MapLight dives despite positive data for schizophrenia drug”
The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.
Original title: “Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug”
Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.
Original title: “Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail”